Literature DB >> 24594371

A mathematical model for pancreatic cancer growth and treatments.

Yoram Louzoun1, Chuan Xue2, Gregory B Lesinski3, Avner Friedman4.   

Abstract

Pancreatic cancer is one of the most deadly types of cancer and has extremely poor prognosis. This malignancy typically induces only limited cellular immune responses, the magnitude of which can increase with the number of encountered cancer cells. On the other hand, pancreatic cancer is highly effective at evading immune responses by inducing polarization of pro-inflammatory M1 macrophages into anti-inflammatory M2 macrophages, and promoting expansion of myeloid derived suppressor cells, which block the killing of cancer cells by cytotoxic T cells. These factors allow immune evasion to predominate, promoting metastasis and poor responsiveness to chemotherapies and immunotherapies. In this paper we develop a mathematical model of pancreatic cancer, and use it to qualitatively explain a variety of biomedical and clinical data. The model shows that drugs aimed at suppressing cancer growth are effective only if the immune induced cancer cell death lies within a specific range, that is, the immune system has a specific window of opportunity to effectively suppress cancer under treatment. The model results suggest that tumor growth rate is affected by complex feedback loops between the tumor cells, endothelial cells and the immune response. The relative strength of the different loops determines the cancer growth rate and its response to immunotherapy. The model could serve as a starting point to identify optimal nodes for intervention against pancreatic cancer.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Immune response; Immunotherapy; Pancreatic cancer

Mesh:

Substances:

Year:  2014        PMID: 24594371      PMCID: PMC4011486          DOI: 10.1016/j.jtbi.2014.02.028

Source DB:  PubMed          Journal:  J Theor Biol        ISSN: 0022-5193            Impact factor:   2.691


  43 in total

1.  Pancreatic stellate cells are activated by proinflammatory cytokines: implications for pancreatic fibrogenesis.

Authors:  M V Apte; P S Haber; S J Darby; S C Rodgers; G W McCaughan; M A Korsten; R C Pirola; J S Wilson
Journal:  Gut       Date:  1999-04       Impact factor: 23.059

2.  A phase II trial of nab-Paclitaxel as second-line therapy in patients with advanced pancreatic cancer.

Authors:  Peter J Hosein; Gilberto de Lima Lopes; Vitor H Pastorini; Christina Gomez; Jessica Macintyre; Gloria Zayas; Isildinha Reis; Alberto J Montero; Jaime R Merchan; Caio M Rocha Lima
Journal:  Am J Clin Oncol       Date:  2013-04       Impact factor: 2.339

Review 3.  The pancreatic stellate cell: a star on the rise in pancreatic diseases.

Authors:  M Bishr Omary; Aurelia Lugea; Anson W Lowe; Stephen J Pandol
Journal:  J Clin Invest       Date:  2007-01       Impact factor: 14.808

4.  FOLFIRINOX in locally advanced pancreas adenocarcinoma: back to the future?

Authors:  Tanios Bekaii-Saab; Richard M Goldberg
Journal:  Oncologist       Date:  2013

5.  Expression of transforming growth factor-beta 1 by pancreatic stellate cells and its implications for matrix secretion and turnover in chronic pancreatitis.

Authors:  Fanny Wai-Tsing Shek; Robert Christopher Benyon; Fiona Mairi Walker; Peter Raymond McCrudden; Sylvia Lin Foon Pender; Elizabeth Jean Williams; Penelope Ann Johnson; Colin David Johnson; Adrian Calvin Bateman; David Roger Fine; John Peter Iredale
Journal:  Am J Pathol       Date:  2002-05       Impact factor: 4.307

Review 6.  Pancreatic cancer: advances in treatment, results and limitations.

Authors:  Thilo Hackert; Markus W Büchler
Journal:  Dig Dis       Date:  2013-06-17       Impact factor: 2.404

7.  Induction of Th17 cells in the tumor microenvironment improves survival in a murine model of pancreatic cancer.

Authors:  Jennifer L Gnerlich; Jonathan B Mitchem; Joshua S Weir; Narendra V Sankpal; Hiroyuki Kashiwagi; Brian A Belt; Matthew R Porembka; John M Herndon; Timothy J Eberlein; Peter Goedegebuure; David C Linehan
Journal:  J Immunol       Date:  2010-08-30       Impact factor: 5.422

8.  Tumor-derived granulocyte-macrophage colony-stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer.

Authors:  Lauren J Bayne; Gregory L Beatty; Nirag Jhala; Carolyn E Clark; Andrew D Rhim; Ben Z Stanger; Robert H Vonderheide
Journal:  Cancer Cell       Date:  2012-06-12       Impact factor: 31.743

Review 9.  Pancreatic stellate cells--role in pancreas cancer.

Authors:  Max G Bachem; Shaoxia Zhou; Karin Buck; Wilhelm Schneiderhan; Marco Siech
Journal:  Langenbecks Arch Surg       Date:  2008-01-17       Impact factor: 3.445

10.  Therapeutic efficacy of bifunctional siRNA combining TGF-β1 silencing with RIG-I activation in pancreatic cancer.

Authors:  Jonathan Ellermeier; Jiwu Wei; Peter Duewell; Sabine Hoves; Mareike R Stieg; Tina Adunka; Daniel Noerenberg; Hans-Joachim Anders; Doris Mayr; Hendrik Poeck; Gunther Hartmann; Stefan Endres; Max Schnurr
Journal:  Cancer Res       Date:  2013-01-21       Impact factor: 12.701

View more
  16 in total

1.  Bifurcation-based approach reveals synergism and optimal combinatorial perturbation.

Authors:  Yanwei Liu; Shanshan Li; Zengrong Liu; Ruiqi Wang
Journal:  J Biol Phys       Date:  2016-04-14       Impact factor: 1.365

2.  CA19-9-related tumor kinetics after first-line chemotherapy of patients with advanced pancreatic cancer: a monoinstitutional experience.

Authors:  Giuseppe Colloca; Antonella Venturino; Domenico Guarneri
Journal:  Med Oncol       Date:  2016-08-13       Impact factor: 3.064

3.  Modeling the Dichotomy of the Immune Response to Cancer: Cytotoxic Effects and Tumor-Promoting Inflammation.

Authors:  Kathleen P Wilkie; Philip Hahnfeldt
Journal:  Bull Math Biol       Date:  2017-06-05       Impact factor: 1.758

Review 4.  Local and Systemic Expression of Immunomodulatory Factors in Chronic Pancreatitis.

Authors:  Hannah M Komar; Phil A Hart; Zobeida Cruz-Monserrate; Darwin L Conwell; Gregory B Lesinski
Journal:  Pancreas       Date:  2017-09       Impact factor: 3.327

5.  Modeling the effects of EMT-immune dynamics on carcinoma disease progression.

Authors:  Daniel R Bergman; Matthew K Karikomi; Min Yu; Qing Nie; Adam L MacLean
Journal:  Commun Biol       Date:  2021-08-18

6.  Dynamic interplay between tumour, stroma and immune system can drive or prevent tumour progression.

Authors:  R J Seager; Cynthia Hajal; Fabian Spill; Roger D Kamm; Muhammad H Zaman
Journal:  Converg Sci Phys Oncol       Date:  2017-07-28

7.  Mathematical Modeling to Address Challenges in Pancreatic Cancer.

Authors:  Prashant Dogra; Javier R Ramírez; María J Peláez; Zhihui Wang; Vittorio Cristini; Gulshan Parasher; Manmeet Rawat
Journal:  Curr Top Med Chem       Date:  2020       Impact factor: 3.295

8.  Mathematical modeling of ventilator-induced lung inflammation.

Authors:  Sarah Minucci; Rebecca L Heise; Michael S Valentine; Franck J Kamga Gninzeko; Angela M Reynolds
Journal:  J Theor Biol       Date:  2021-04-27       Impact factor: 2.405

9.  Serum uPAR as Biomarker in Breast Cancer Recurrence: A Mathematical Model.

Authors:  Wenrui Hao; Avner Friedman
Journal:  PLoS One       Date:  2016-04-14       Impact factor: 3.240

10.  Modeling the Treatment of Glioblastoma Multiforme and Cancer Stem Cells with Ordinary Differential Equations.

Authors:  Kristen Abernathy; Jeremy Burke
Journal:  Comput Math Methods Med       Date:  2016-01-18       Impact factor: 2.238

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.